2seventy Bio Inc (TSVT) - News Archive

In a year marked by resilience and strategic refocusing, 2seventy bio, Inc. (Nasdaq: TSVT), has made significant strides in its efforts to establish a robust foothold within the biopharmaceutical industry. From achievin...

: The biotechnology sector continues to be a dynamic and volatile industry, characterized by rapid advancements in research and development juxtaposed against rigorous regulatory scrutiny and volatile market behaviors....

CSIMarket.com : Edition September 27, 2024 Investigation Launched into 2seventy bio, Inc.: Investors Urged to Collaborate NEW YORK The renowned legal establishment of Bronstein, Gewirtz, and Grossman, LLC, hath declared...

2seventy bio and Bristol Myers Squibb Discontinue Phase 3 KarMMa-9 Study Enrollment Amid Promising Q3 Financial Outlook CAMBRIDGE, Mass. - 2seventy bio, Inc. (Nasdaq: TSVT) recently announced a significant strategic dev...

In a compelling display of corporate metamorphosis, 2seventy bio, Inc. (NASDAQ: TSVT) has unveiled its financial results for Q2 2024, which depict a rollercoaster journey marked by both extraordinary growth and the spec...

In a recent development, Novo Nordisk has completed the acquisition of 2seventy Bio s Hemophilia A program and the rights to their innovative in vivo gene editing technology. This transaction signifies Novo Nordisk s ef...

In a recent development, Novo Nordisk has completed the acquisition of 2seventy bio, Inc. s Hemophilia A program and the rights to their in vivo gene editing technology (excluding oncology and gene editing for autologou...

Biotechnology company 2seventy bio, Inc.’s recent financial and operational strides shed a promising light on their intensified focus on making groundbreaking cancer therapy Abecma more accessible and returning to comme...

The biopharmaceutical industry continues to witness significant advancements and breakthroughs, with companies like 2seventy bio, Inc. at the forefront of innovation. On May 8, 2024, 2seventy bio will announce, through...

2seventy bio Reiterates Commitment to Maximizing Shareholder ValueCAMBRIDGE, Mass. - In a bold move that sets the stage for future success, 2seventy bio, Inc. (NASDAQ: TSVT), a pioneering immuno-oncology cell therapy co...